Royalty Pharma PLC

RPRX Healthcare Biotechnology

Royalty Pharma PLC’s revenue for fiscal 2025 (year ended December 2025) was $2.4 billion, up 5.06% from fiscal 2024.

Revenue
+13.3%
EPS
−51.5%
Free cash flow
+364.6%
Total debt
−4.00%

Quarter to September 2026, against a year earlier

67.25 0.32 −0.47%
Market cap
$39.0B
P/E
44.8×
Fwd P/E
27.3×
Dividend yield
1.37%
F-score
5/9
Altman Z
1.61
Beneish M
−2.83
Dividend safety
41/100

Royalty Pharma PLC (RPRX) Book value per share

Alert me on Book value per share

Royalty Pharma PLC's book value per share at the end of fiscal 2025 was 22.6×, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was 22.0×. Over the past ten years it has ranged from 0.0× (fiscal 2018) to 26.4× (fiscal 2020); the current reading is higher than 63% of that period. Royalty Pharma PLC ranks 31st of 611 Biotechnology companies by book value per share.

Book value per share, annual

Embed this chart

Annual newest first

Period Book value per share Change
FY2025 22.6× (2.05%)
FY2024 23.1× 2.43%
FY2023 22.5× 3.59%
FY2022 21.7× (11.97%)
FY2021 24.7× (6.26%)
FY2020 26.4× 61.13%
FY2019 16.4× —
FY2018 0.0× —

Quarterly newest first

Period Book value per share Change
Sep 2026 22.0× (0.12%)
Jun 2026 22.0× (3.35%)
Mar 2026 22.7× 0.65%
Dec 2025 22.6× 1.47%
27 more quarters

Against its own ten years

Low 0.0× High 26.4×
Ten-year median 22.6×
Current reading's percentile 63

Book value per share against peers

What Book value per share is

BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.

(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))

The full definition of Book value per share →

More on RPRX